Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026